Annovis Bio Inc (ANVS NYSE) stock market data APIs
$3.668
0.01(0.3%)
as of December 18, 2025
Try our APIs with
free plan!
Annovis Bio Inc Financial Data Overview
Price chart is built with
Anychart
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzheimer's disease and dementia. The company was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Prev. Close
3.668
Open
3.6797
High
3.8717
Low
3.6622
52 wk Range
1.11-5.6
Market Cap
59 803 K
Shares Outstanding
26 115 K
EPS
-0.37
Beta
1.614
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Annovis Bio Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Annovis Bio Inc data using free add-ons & libraries
Get Annovis Bio Inc Fundamental Data
Annovis Bio Inc Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-05
- EPS/Forecast: -0.305
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Annovis Bio Inc News
New
Annovis Plans 36-Month Extension Study To Further Evaluate Buntanetap In Parkinson's
(RTTNews) - Annovis Bio, Inc. (ANVS) is preparing to launch a long-term open-label extension study to observe how Parkinson's disease patients respond to continued treatment with Buntanetap over three...
Annovis Announces Two Presentations at the CTAD 2025 Conference
MALVERN, Pa., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies f...
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
MarketNewsUpdatesNews Commentary NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The advance anti-aging therapies market is expanding quickly fueled by a larger senior population and increased consumer...
Annovis Bio announces $3.4 million registered direct offering of common stock priced at-the-market under the NYSE rules
* Annovis Bio(NYSE:ANVS [https://seekingalpha.com/symbol/ANVS]) said on Monday it has entered into definitive agreements for a registered direct offering of 1,670,732 shares of common stock at $2.05...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
